822 results on '"Mirabella, Massimiliano"'
Search Results
2. A case report of cladribine‐induced IgG4-associated liver injury
3. COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients
4. Tumefactive Demyelinating Lesion Around a Developmental Venous Anomaly: A Rare Association
5. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
6. Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study
7. NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab
8. Optical Coherence Tomography Advanced Parameters in Patients With Multiple Sclerosis: Ophthalmological and Neurological Assessments
9. Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience
10. New onset of Susac syndrome after mRNA COVID-19 vaccine: a case report
11. CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis
12. A true isolated cognitive relapse in multiple sclerosis
13. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.
14. Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients
15. Neurosarcoidosis presenting as longitudinally extensive myelitis: Diagnostic assessment, differential diagnosis, and therapeutic approach
16. Challenges in Diagnosis and Therapeutic Strategies in Late-Onset Multiple Sclerosis
17. Covid-19 Outbreak in Italy: An Opportunity to Evaluate Extended Interval Dosing of Ocrelizumab in MS Patients (P2-6.010)
18. A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy
19. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies
20. Cladribine effects on patient-reported outcomes and their clinical and biometric correlates in highly active relapsing multiple sclerosis at first switch: the observational, multicenter, prospective, phase IV CLADFIT-MS study.
21. Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients
22. Hospital admissions from the emergency department of adult patients affected by myopathies
23. The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
24. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study
25. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study
26. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
27. A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis
28. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
29. Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant?
30. Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab
31. Different HLA genotype pattern in patients with Multiple Sclerosis onset after COVID-19 vaccine.
32. Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study
33. Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod
34. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context
35. Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study
36. Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study
37. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
38. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
39. Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study.
40. Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study
41. Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review
42. Serum-Circulating microRNAs in Sporadic Inclusion Body Myositis
43. Hereditary inclusion-body myopathies
44. List of contributors
45. Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity
46. Potential Effect of Cyclophosphamide on Bleb Survival in Five Patients with Multiple Sclerosis Who Underwent Glaucoma Surgery
47. Effectiveness of Ocrelizumab in Primary PrOgRessive mulTiple sclerosis: a mUlticeNter, retrospective, real-world sTudY (OPPORTUNITY)
48. COVID-19 presenting as a non-arteritic anterior ischemic optic neuropathy.
49. Sporadic late-onset nemaline myopathy: clinical, pathology and imaging findings in a single center cohort
50. Systematic assessment and characterization of chronic pain in multiple sclerosis patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.